Protective effects of sodium para-amino salicylate on manganese-induced neuronal death: The involvement of reactive oxygen species

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 11, 2009, Pages 1563-1569

  Yoon, Hyonok ^a   Kim, Do Sung ^a   Lee, Geum Hwa ^a   Kim, Ji Ye ^b   Kim, Diana H ^d   Kim, Kee Won ^a   Chae, Soo Wan ^a   You, Wan Hee ^a   Lee, Yong Chul ^a   Park, Seoung Ju ^a   Kim, Hyung Ryong ^c   Chae, Han Jung ^a  

^a Chonbuk National University   (South Korea)

^b Yonsei University   (South Korea)

^c Wonkwang University   (South Korea)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis; Manganese; Manganism; PAS Na; ROS

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ACETOACETIC ACID; AMINOSALICYLIC ACID; ANTIINFECTIVE AGENT; CASPASE 3; DICHLOROFLUORESCEIN; MANGANESE CHLORIDE; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MORPHOLOGY; NERVE CELL NECROSIS; NERVE DEGENERATION; STAINING; TUBERCULOSIS;

EID: 75749099848     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.11.0017     Document Type: Article

References (39)

1. Monnet-Tschudi F et al. Involvement of environmental mercury and lead in the etiology of neurodegenerative diseases. Rev Environ Health 2006; 21: 105-117.
2. Changcheng Song et al. The heavy metal cadmium induces valosin-containing protein (VCP)-mediated aggresome formation. Toxicol Appl Pharmacol 2008; 228: 351-363.
3. Kessler KR et al. Secondary progressive chronic manganism associated with markedly decreased striatal D2 receptor density. Mov Disord 2003; 18: 217-218.
4. Bonne Hernández R et al. Distribution and behavior of manganese in the Alto do Paranapanema Basin. J Environ Monit 2009; 11: 1236-1243.
5. Gulson B et al. Changes in manganese and lead in the environment and young children associated with the introduction of methylcyclopentadienyl manganese tricarbonyl in gasoline - preliminary results. Environ Res 2006; 100: 100-114.
6. Pfeifer GD et al. Health and environmental testing of manganese exhaust products from use of methylcyclopentadienyl manganese tricarbonyl in gasoline. Sci Total Environ 2004; 334: 397-408.
7. Elder A et al. Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environ Health Perspect 2006; 114: 1172-1178.
8. Gorell JM et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 1999; 20: 239-247.
9. Gorell JM et al. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 1997; 48: 650-658.
10. Finkelstein MM, Jerrett MA. A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. Environ Res 2007; 104: 420-432.
11. Finkelstein MM et al. Basal ganglia neurotransmitter concentrations in rhesus monkeys following subchronic manganese sulfate inhalation. Am J Ind Med 2007; 50: 772-778.
12. Yamada M et al. Chronic manganese poisoning: a neuropathological study with determination of manganese distribution in the brain. Acta Neuropathol 1986; 70: 273-278.
13. Asanuma M et al. Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases. Curr Pharm Des 2004; 10: 695-700.
14. Aschner M et al. Manganese: recent advances in understanding its transport and neurotoxicity. Toxicol Appl Pharmacol 2007; 221: 131-147.
15. Jiang YM et al. Effective treatment of manganese-induced occupational Parkinsonism with p-aminosalicylic acid: a case of 17-year follow-up study. J Occup Environ Med 2006; 48: 644-649.
16. Ky SQ et al. A report of two cases of chronic serious manganese poisoning treated with sodium para-aminosalicylic acid. Br J Ind Med 1992; 49: 66-69.
17. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002; 1: 111-121.
18. Kim DS et al. Inhibitory effects of rosmarinic acid on adriamycin-induced apoptosis in H9c2 cardiac muscle cells by inhibiting reactive oxygen species and the activations of c-Jun N-terminal kinase and extracellular signal-regulated kinase. Biochem Pharmacol 2005; 70: 1066-1078.
19. Huang CC et al. Progression after chronic manganese exposure. Neurology 1993; 43: 1479-1483.
20. Vezér T et al. Behavioral effects of subchronic inorganic manganese exposure in rats. Am J Ind Med 2007; 50: 841-852.
21. Baldwin M et al. Bioindicator and exposure data for a population based study of manganese. Neurotoxicology 1999; 20: 343-353.
22. Mergler D et al. Manganese neurotoxicity, a continuum of dysfunction: results from a community based study. Neurotoxicology 1999; 20: 327-342.
23. Hirata Y et al. Manganese mimics the action of 1-methyl-4-phenylpyridinium ion, a dopaminergic neurotoxin, in rat striatal tissue slices. Neurosci Lett 2001; 311: 53-56.
24. Gunter KK et al. Determining the oxidation states of manganese in PC12 and nerve growth factor-induced PC12 cells. Free Radic Biol Med 2005; 39: 164-181.
25. Desole MS et al. Glutathione deficiency potentiates manganese toxicity in rat striatum and brainstem and in PC12 cells. Pharmacol Res 1997; 36: 285-292.
26. Desole MS et al. Cellular defence mechanisms in the striatum of young and aged rats subchronically exposed to manganese. Neuropharmacology 1995; 34: 289-295.
27. Valko M et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
28. Palmieri B, Sblendorio V. Oxidative stress detection: what for? Part II. Eur Rev Med Pharmacol Sci 2007; 11: 27-54.
29. Patel RP et al. Biological aspects of reactive nitrogen species. Biochim Biophys Acta 1999; 1411: 385-400.
30. Stadtman ER. Protein oxidation and aging. Science 1992; 257: 1220-1224.
31. Liu J et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci USA 2002; 99: 2356-2361.
32. Klockgether T, Turski L. Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci 1989; 12: 285-286.
33. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408: 239-247.
34. Newland M C et al. Visualizing manganese in the primate basal ganglia with magnetic resonance imaging. Exp Neurol 1989; 106: 251-258.
35. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995; 1241: 139-176.
36. Zoratti M et al. Mitochondrial permeability transitions: how many doors to the house? Biochim Biophys Acta 2005; 1706: 40-52.
37. Simmonds NJ et al. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies. Aliment Pharmacol Ther 1999; 13: 363-372.
38. Yppolito R et al. On the antioxidant properties of therapeutic drugs: quenching of singlet molecular oxygen by aminosalicylic acids. Redox Rep 2002; 7: 229-233.
39. Yin Z et al. Mitochondrial-dependent manganese neurotoxicity in rat primary astrocyte cultures. Brain Res 2008; 1203: 1-11.